Evotec's Science Wins Keep Landing in a Market That Only Counts the Losses

Evotec shares near 52-week low as slashed 2026 guidance overshadows partnership news and a Pentagon antibody contract.

Evotec has spent the past few weeks doing two things at once: announcing partnerships that ought to burnish its reputation as a drug-discovery specialist, and watching its share price slide further anyway. That gap between operational news and market reaction is the real story here — a case study in how hard it has become for contract researchers to convert scientific progress into investor confidence.

The stock closed Wednesday at EUR 3.17, a mere 1.4% above the 52-week low of EUR 3.12 set just days earlier. It sits roughly 59% below its annual high of EUR 7.75. Year-to-date the shares have shed 42%, and over twelve months the decline reaches 46%. An RSI reading of 34.2 flags oversold conditions, though that signal has rarely produced a lasting bounce in recent months.

A Cut Forecast That Still Echoes

About four weeks ago, Evotec confirmed its already-reduced 2026 guidance alongside final half-year figures. First-half revenue fell 19.2% to EUR 300.1 million, down from EUR 371.2 million a year earlier, while adjusted EBITDA came in at minus EUR 42.7 million.

For the full year, management now expects revenue of EUR 570 million to EUR 610 million — well short of the original EUR 700 million to EUR 780 million target. On adjusted EBITDA, the company had initially guided for a range of EUR 0 to EUR 40 million; it now anticipates a loss of EUR 70 million to EUR 105 million.

The stated culprits: delays in existing strategic partnerships and lower-than-expected contributions from potential new collaborations, which are now not expected to bear fruit until 2027. That deferral explains a substantial chunk of the guidance reduction, even if the precise split cannot be pinned to a single tidy figure. What matters for shareholders is that the business hasn't vanished — it has simply slipped to the right. Whether that counts as consolation or merely a postponed disappointment won't be clear until 2027.

Partnerships as a Counter-Narrative

Alongside the grim headline numbers, Evotec is trying to paint a different picture through deal-making. A little over a week ago, it launched a research collaboration with Plectonic Biotech, pairing Evotec's BiTCo platform with the partner's LOGIBODY technology to explore T-cell-engaging approaches against solid tumors.

Back in early August, an AI-driven partnership with Odyssey Therapeutics kicked off in autoimmune and inflammatory diseases. Neither announcement halted the stock's decline: since the Plectonic news, the shares have lost another 3.8%, and since the Odyssey tie-up, 8.3%.

That is the irony at the heart of the situation. Evotec remains technologically active in its core business, Just-Evotec Biologics is reportedly running at high capacity utilization, and in Discovery & Preclinical Development, net sales excluding strategic partnerships climbed 28% in the first half. Yet the market is in no mood to reward operational wins while the big guidance question hangs overhead.

A Pentagon Contract That Barely Registers

The clearest example of that disconnect arrived Wednesday, when Just-Evotec Biologics advanced JST-018 — an antibody cocktail against orthopoxviruses, meaning smallpox and mpox — into Phase I clinical testing. The client is the U.S. Department of Defense, and the program runs under its Accelerated Antibodies Program.

Combined with the plague antibody program launched in 2022, the contract volume totals up to USD 123.9 million. Production takes place at the J.POD facility in Redmond, Washington, supported by the company's in-house AI design platform. That the Pentagon has now placed its second antibody program with Just-Evotec Biologics suggests the technology platform is viewed as dependable — a meaningful signal for a company whose recent narrative has centered on cost-cutting and prioritization, and one backed by a counterparty synonymous with solvency and planning certainty.

The market's response? The stock traded slightly lower on the day and sits at EUR 3.17. That is the problem in a nutshell: Evotec is currently priced not on individual program successes but on the overall picture, and that picture remains strained. Numbers like these overshadow even a valid clinical milestone.

The Chart Tells Its Own Story

Technically, the shares are locked in a structural downtrend rather than suffering a single bad session. Add the broader market backdrop: the DAX itself came under pressure Wednesday, weighed down by oil prices and anticipation of the upcoming ECB rate decision. In such an environment, mid-caps with a battered story naturally struggle to swim against the current — even when they carry good news.

Governance and Cost-Cutting

Uncertainty has been compounded by a change at the top of Evotec's supervisory board. Roughly a month ago, Camilla Macapili Languille — an independent board member since June 2022 and part of the Audit & Compliance Committee — stepped down. Investors rarely read such departures as neutral, even when the reasons stay unclear.

On the cost side, Evotec has countered with its "Horizon" transformation program, targeting annual savings of EUR 75 million by the end of 2027. For 2026, the company already expects a cost contribution equal to 20% to 30% of that figure. Whether that is enough to win back investor trust is a different question from whether the program works technically.

Takeover Chatter as a Second Narrative

Alongside the JST-018 news, speculation about potential takeover interest in Evotec circulated Wednesday, accompanied by analyst commentary on the company's potential. It fits the pattern: when a stock has fallen this far, the underlying substance — valid technology platforms, functioning partnerships with government clients, a diversified pipeline — eventually becomes more interesting than the current market capitalization of around EUR 570 million. That is less coincidence than the logical consequence of a valuation that barely rewards operational progress anymore.

Evotec will report final third-quarter figures on November 5. Until then, the stock remains what it has been for months: a case in which operational advances and a slashed annual forecast stand in irreconcilable tension — with the share price, so far, firmly siding with the latter. The Pentagon milestone demonstrates that Just-Evotec Biologics is taken seriously as a contract developer for government programs, and that matters more over the long run than Wednesday's price action suggests. Near term, though, skepticism about the share price outweighs optimism, even as the technological foundation leaves room for a later re-rating.